Skip to content

Study of the Scandinavian Total Ankle Replacement (STAR) for the Treatment of Bilateral Degenerative Ankle Disease

Investigational Device Exemption for the Scandinavian Total Ankle Replacement (STAR) - Bilateral Arm

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00586781
Enrollment
21
Registered
2008-01-04
Start date
2001-09-30
Completion date
Unknown
Last updated
2008-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis, Post-Traumatic Arthritis, Rheumatoid Arthritis

Keywords

ankle replacement, end-stage arthritis of the ankle, degenerative ankle disease

Brief summary

The purpose of this study is to evaluate the safety of the S.T.A.R. device for patients with bilateral disease.

Detailed description

The specific objectives are to show that the safety data of the S.T.A.R. ankle arthroplasty is similar for treatment of single ankle disease (as defined in the pivotal study) and bilateral ankle disease. The bilateral disease may be identified at the time of enrollment or may have progressed after enrollment and treatment of the first ankle in the pivotal study.

Interventions

DEVICEScandinavian Total Ankle Replacement (STAR)

The device has three parts: two metal bearing surfaces (cobalt-chromium alloy) plates with bars that fit into the bone and one plastic (polyethylene) spacer that moves between the metal plates like a ball bearing. The materials in the S.T.A.R. device are the same materials used in total hip and knee implants.

Sponsors

Link America, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Moderate or severe pain, loss of mobility and function of the ankle * Primary arthrosis, post traumatic arthrosis or rheumatoid arthrosis * At least six months of conservative treatment for severe ankle conditions * Bilateral ankle disease that have not been enrolled in the pivotal study or single ankle disease and enrolled in the pivotal study but have subsequently developed ankle disease in the contralateral ankle and require surgical intervention * Willing and able to give informed consent

Exclusion criteria

* Patients who have not reached skeletal maturity * Active or prior deep infection in the ankle joint or adjacent bones * Prior arthrodesis at the involved site * History of prior mental illness or patient demonstrates that their mental capacity may interfere with their ability to follow the study protocol * Obesity (weight greater than 250 lbs) * History of current or prior drug abuse or alcoholism * Any physical condition precluding major surgery * Prior surgery and/or injury that has adversely affected the ankle bone stock * Severe osteoporotic or osteopenic condition or other conditions that may lead to inadequate implant fixation in the bone * Insufficient ligament support

Design outcomes

Primary

MeasureTime frame
Safety endpoints to be measured are: • Device failure or device removal/revision • Radiographically confirmed loosening and migration • Complications12 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026